Trial Profile

Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Tremelimumab (Primary)
Indications Carcinoma; Gastric cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

27 Feb 2024 Status changed from active, no longer recruiting to completed.
21 Jan 2023 Results (n=48) from phase II portion of this trial presented at the 2023 Gastrointestinal Cancers Symposium
30 Dec 2022 Planned End Date changed from 30 Jun 2021 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com